RCEL AVITA Medical, Inc. stock chart & analysis
Conviction 4HealthcareScan · Fri, Nov 6, 2026AVITA Medical, Inc. (RCEL) closed at $16.59 (+5.80%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 67, RS Rating 99, -7.9% from its 52-week high, +380.3% year to date. Sector: Healthcare · Surgical & Medical Instruments & Apparatus.
Why RCEL moved
From the StockSetups movers recaps that covered RCEL, newest first. A recap states what was known that day.
- Close+63.4%
AVITA filed an 8-K earnings report and a 10-Q on August 6, along with an 8-K/A vote filing. The market responded decisively positively, pushing the stock to fresh annual highs.
Top Stock Movers Today — August 7, 2026: Why WWR, VATE, RCEL, QNST & OABI Surged →
Financials as of Wed, Sep 30, 2026 · quarterly.
RCEL technical analysis
Trend
RCEL is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 29.8% above the 50-day ($12.77) and 141.8% above the 200-day ($6.85). ADX(14) at 42 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 67, in the bullish half of its range. MACD crossed below its signal line 3 sessions ago. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 2.6× its 20-day average. It trades about $7.7M a day on average. ATR(14) is $1.07, 6.4% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.14) shows accumulation.
Key levels
The chart pattern's support is $12.75 and its resistance $16.76. The 52-week range is $3.22 to $17.99; price is 7.9% below the high and 414.6% above the low. The VWAP anchored at the 52-week high is $16.87, above price.
Performance
RCEL returned +5.9% (1 week), +24.3% (1 month), +118.0% (3 months), +303.2% (6 months), +373.4% (1 year), +380.3% (year to date).
About AVITA Medical, Inc.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Surgical & Medical Instruments & Apparatus · Listed 2012 · 226 employees
Signal lifecycle
How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.
- Breaking out nowAug 251 scan
- Setting upAug 31 – Sep 12 scans
- Breaking out nowSep 21 scan
- Setting upSep 17 – Sep 213 scans
- Breaking out nowSep 221 scan
- Setting upOct 16 – Oct 192 scans
Insider activity
SEC Form 4 transactions in RCEL · open-market 4 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
O'Toole David D CFO · Common Stock · 2026-06-12 | Buy | 2K | $8K | 2026-06-12 | 2026-08-24 |
O'Toole David D CFO · Common Stock · 2026-06-12 | Grant | 2K | $8K | 2026-06-12 | 2026-06-12 |
Woody Joseph Fralin Director · Common Stock · 2026-06-09 | Buy | 5.2K | $21K | 2026-06-09 | 2026-06-10 |
Woody Joseph Fralin Director · Common Stock · 2026-06-09 | Buy | 5K | $21K | 2026-06-09 | 2026-06-09 |
Woody Joseph Fralin Director · Common Stock · 2026-06-03 | Buy | 5K | $20K | 2026-06-03 | 2026-06-05 |
REED JAN STERN Director · Stock Options (Right to Buy) · 2026-01-20 | Grant | 16.13K | $0 | 2026-01-20 | 2026-06-04 |
Woody Joseph Fralin Director · Stock Options (Right to Buy) · 2026-01-20 | Grant | 16.13K | $0 | 2026-01-20 | 2026-06-04 |
McNamara Robert Director · Common Stock · 2026-01-20 | Grant | 22.21K | — | 2026-01-20 | 2026-06-04 |
REED JAN STERN Director · Common Stock · 2026-01-20 | Grant | 22.21K | — | 2026-01-20 | 2026-06-04 |
Tarnoff Michael E Director · Stock Options (Right to Buy) · 2026-01-20 | Grant | 16.13K | $0 | 2026-01-20 | 2026-06-04 |
SEC filings
EDGAR filings in RCEL · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.